CT-guided radioactive ¹²⁵I seed implantation therapy of symptomatic retroperitoneal lymph node metastases.

PURPOSE: This study explored the clinical efficacy of CT-guided radioactive (125)I seed implantation in treating patients with symptomatic retroperitoneal lymph node metastases.

METHODS

Twenty-five patients with pathologically confirmed malignant tumors received CT-guided radioactive (125)I seed implantation to treat metastatic lymph nodes. The diameter of the metastatic lymph nodes ranged from 1.5 to 4.5 cm. Treatment planning system (TPS) was used to reconstruct the three-dimensional image of the tumor and then calculate the corresponding quantity and distribution of (125)I seeds.

RESULTS

Follow-up period for this group of patients was 2-30 months, and median time was 16 months. Symptoms of refractory pain were significantly resolved postimplantation (P < 0.05), and Karnofsky score rose dramatically (P < 0.05). Most patients reported pain relief 2-5 days after treatment. Follow-up imaging studies were performed 2 months later, which revealed CR in 7 patients, PR in 13 patients, SD in 3 patients, and PD in 2 patients. The overall effective rate (CR + PR) was 80 %. Median survival time was 25.5 months. Seven patients died of recurrent tumor; 16 patients died of multiorgan failure or other metastases. Two patients survived after 30 months follow-up. Two patients reported localized skin erythema 1 week postimplantation, which disappeared after topical treatment.

CONCLUSIONS

CT-guided radioactive (125)I seed implantation, which showed good palliative pain relief with acceptable short-term effects, has proved in our study to be a new, safe, effective, and relatively uncomplicated treatment option for symptomatic retroperitoneal metastatic lymph nodes.